LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.

被引：0
|
作者：
Jonasch, Eric
Iliopoulos, Othon
Rathmell, Wendy Kimryn
Narayan, Vivek
Maughan, Benjamin L.
Oudard, Stephane
Else, Tobias
Maranchie, Jodi K.
Welsh, Sarah Joanne
Iversen, Ane Bundsbaek Bondergaard
Roy, Ananya
Liu, Yanfang
Perini, Rodolfo F.
Linehan, W. Marston
Srinivasan, Ramaprasad
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Univ Penn, Philadelphia, PA USA
[6] Univ Utah, Salt Lake City, UT USA
[7] Univ Paris, Georges Pompidou Hosp, Paris, France
[8] Univ Michigan, Ann Arbor, MI USA
[9] Univ Pittsburgh, Pittsburgh, PA USA
[10] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[11] Aarhus Univ Hosp, Aarhus, Denmark
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Natl Canc Inst, Ctr Canc Res, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4546
引用
收藏
页数：1
相关论文
共 21 条
  • [1] Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study
    Srinivasan, R.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V.
    Maughan, B. L.
    Oudard, S.
    Else, T.
    Maranchie, J. K.
    Welsh, S. J.
    Iversen, A. B. Bondergaard
    Chen, K.
    Perini, R. F.
    Liu, Y.
    Linehan, W. M.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1433 - S1434
  • [2] Belzutifan, a hypoxia-inducible factor-2α ( HIF-2α) inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: Long-term results of the phase 2 LITESPARK-004 study
    Srinivasan, Ramaprasad
    Iliopoulos, Othon
    Beckermann, Kathryn E.
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Iversen, Ane B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Jonasch, Eric
    CANCER RESEARCH, 2024, 84 (07)
  • [3] Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
    Else, Tobias
    Jonasch, Eric
    Iliopoulos, Othon
    Beckermann, Kathryn E.
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Maranchie, Jodi K.
    Iversen, Ane B.
    Goldberg, Cynthia M.
    Fu, Wei
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    CLINICAL CANCER RESEARCH, 2024, 30 (09) : 1750 - 1757
  • [4] Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Srinivasan, Ramaprasad
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah Joanne
    Roy, Ananya
    Liu, Yanfang
    Perini, Rodolfo F.
    Linehan, W. Marston
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease
    Wiley, Henry
    Coleman, Hanna
    Jonasch, Eric
    Srinivasan, Ramaprasad
    Donskov, Frede
    Kruse, Anders
    Maranchie, Jodi
    Chhablani, Jay
    Else, Tobias
    Demirci, Hakan
    Maughan, Benjamin
    Hartnett, Mary
    Perini, Rodolfo
    Park, Eric
    Chew, Emily
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [6] Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease
    Wiley, Henry E.
    Srinivasan, Ramaprasad
    Maranchie, Jodi K.
    Chhablani, Jay
    Iversen, Ane Bundsbaek Bondergaard
    Kruse, Anders
    Jonasch, Eric
    Gombos, Dan S.
    Else, Tobias
    Demirci, Hakan
    Maughan, Benjamin L.
    Hartnett, M. Elizabeth
    Coleman, Hanna R.
    Fu, Wei
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Chew, Emily Y.
    OPHTHALMOLOGY, 2024, 131 (11) : 1324 - 1332
  • [7] Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study
    Iliopoulos, Othon
    Iversen, Ane Bundsbaek Bondergaard
    Beckermann, Katy
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Fu, Wei
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] BELZUTIFAN FOR VON HIPPEL-LINDAU DISEASE-RELATED CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS: SUBGROUP OF PHASE 2 LITESPARK-004 STUDY
    Iliopoulos, Othon
    Iversen, Ane B.
    Narayan, Vivek
    Maughan, Benjamin L.
    Beckermann, Kathryn E.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Fu, Wei
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Srinivasan, Srinivasan
    Jonasch, Eric
    NEURO-ONCOLOGY, 2023, 25
  • [9] Phase II study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Iliopoulos, Othon
    Jonasch, Eric
    Donskov, Frede
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Perini, Rodolfo F.
    Park, Eric Kristopher
    Linehan, Marston W.
    Srinivasan, Ramaprasad
    Rathmell, Kimryn W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] Belzutifan, an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
    Else, T.
    Jonasch, E.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V. K.
    Maughan, B. L.
    Oudard, S.
    Fu, W.
    Liu, Y.
    Perini, R. F.
    Linehan, W. M.
    Srinivasan, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 172 - 172
123